Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Current Assets: 2010-2025

Historic Current Assets for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Sep 2025 value amounting to $950.6 million.

  • Arrowhead Pharmaceuticals' Current Assets rose 36.69% to $950.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $950.6 million, marking a year-over-year increase of 36.69%. This contributed to the annual value of $950.6 million for FY2025, which is 36.69% up from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Current Assets of $950.6 million as of FY2025, which was up 36.69% from $695.5 million recorded in FY2024.
  • In the past 5 years, Arrowhead Pharmaceuticals' Current Assets registered a high of $950.6 million during FY2025, and its lowest value of $384.6 million during FY2021.
  • In the last 3 years, Arrowhead Pharmaceuticals' Current Assets had a median value of $695.5 million in 2024 and averaged $687.5 million.
  • Data for Arrowhead Pharmaceuticals' Current Assets shows a peak YoY skyrocketed of 66.99% (in 2024) over the last 5 years.
  • Arrowhead Pharmaceuticals' Current Assets (Yearly) stood at $384.6 million in 2021, then rose by 5.38% to $405.3 million in 2022, then increased by 2.76% to $416.5 million in 2023, then spiked by 66.99% to $695.5 million in 2024, then surged by 36.69% to $950.6 million in 2025.